TRVI Projected Dividend Yield
Trevi Therapeutics Inc ( NASDAQ : TRVI )Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. 21 YEAR PERFORMANCE RESULTS |
TRVI Dividend History Detail TRVI Dividend News TRVI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |